Despite therapeutic advancements, fighting cancer requires new allies. Cancer cells can adapt themselves under therapeutic pressure and express tumor antigens that hide from our immune system’s surveillance. This mechanism leads to treatment failure of 90% of patients with solid tumors (16 million in 2022).

Brenus Pharma is a French clinical-stage biotech developing a pioneering discovery platform Stimulated-Tumor-Cell (STC) leading the path of a new generation of immunotherapies. STC doesn’t just fight cancer as it is today; it anticipates how cancer will evolve tomorrow, training the patient’s immune system to recognize and destroy tumors, even as they change.

Brenus Pharma is on the brink of a breakthrough and will start its First in Human study in 2024 in colorectal cancer, killing 9.7 million of patient per year.
They are building a strong portfolio in solid tumors, leveraging our patented STC platform, and surpassing other approaches to change a paradigm in oncology.

The STC Platform mimics patient’s relapsing conditions in vitro to produce next-generation immunotherapies educating patient’s immune system against tumor evolution and mechanisms of relapse.

Thanks to their unique mode of production, the STCs will educate the immune system to the largest number of specific targets of interest, validated with multi-omics analysis and patient’s biopsies databases. Thanks to the standardization of the platform, access to the drug will not be limited by production or price, and they can also anticipate synergies with other innovations (ADC, ICP).

Their first candidate, STC-1010, is focused on metastatic colorectal cancer (mCRC) an urgent unmet need.

–  Therapeutic areas: Primary TA: Metastatic Colo Rectal Cancer (mCRC)
Secondary TA : Pancreas Cancer, Liver cancer, Ovarian Cancer, Solid Tumors

–  Based in: Lyon & Clermont-Ferrand (FRANCE)

–  Employees: 11 – 50

–  Created in: 2020